Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug ...

Shares of telehealth provider Hims & Hers Health Inc. (HIMS) dropped over 3% on Thursday after Cigna Group’s (CI) Evernorth ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Photo: Scott Olson () Getting access to popular weight loss drugs will be simpler and cheaper for some. Health insurer Cigna ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

Only half of health insurer Cigna’s (NYSE:CI) clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company’s pharmacy benefits unit ...

Cigna’s Evernorth unit scored a deal with Eli Lilly and Novo Nordisk to make weight loss drugs more affordable for insured ...

Analysts at Citi and Bank of America (NYSE:BAC) are maintaining a cautious stance on Hims & Hers Health as competition in the GLP-1 space intensifies and growth begins to moderate.